Keisuke Shigeta, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Transitional Cell | 18 | 2024 | 808 | 5.530 |
Why?
|
Ureteral Neoplasms | 10 | 2024 | 111 | 4.990 |
Why?
|
Urologic Neoplasms | 8 | 2022 | 318 | 4.440 |
Why?
|
Urinary Bladder Neoplasms | 27 | 2024 | 2248 | 4.060 |
Why?
|
Laparoscopy | 8 | 2023 | 2148 | 1.610 |
Why?
|
Taxoids | 3 | 2016 | 666 | 1.120 |
Why?
|
Neoplasm Recurrence, Local | 17 | 2023 | 9239 | 1.000 |
Why?
|
Nephrectomy | 3 | 2023 | 1048 | 0.990 |
Why?
|
Kidney Neoplasms | 6 | 2022 | 4260 | 0.990 |
Why?
|
Neoplasms, Second Primary | 2 | 2022 | 1063 | 0.810 |
Why?
|
Watchful Waiting | 2 | 2019 | 491 | 0.800 |
Why?
|
Sutures | 1 | 2019 | 299 | 0.600 |
Why?
|
Thrombin | 1 | 2019 | 598 | 0.580 |
Why?
|
Pneumoperitoneum | 1 | 2017 | 46 | 0.580 |
Why?
|
Aneurysm, False | 1 | 2019 | 276 | 0.570 |
Why?
|
Erectile Dysfunction | 1 | 2020 | 436 | 0.570 |
Why?
|
Cystectomy | 8 | 2024 | 686 | 0.570 |
Why?
|
Fibrinogen | 1 | 2019 | 894 | 0.550 |
Why?
|
Mucin-1 | 1 | 2020 | 544 | 0.530 |
Why?
|
Propensity Score | 6 | 2021 | 1781 | 0.510 |
Why?
|
Cisplatin | 2 | 2020 | 1662 | 0.510 |
Why?
|
Suture Techniques | 1 | 2019 | 797 | 0.490 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2023 | 5170 | 0.490 |
Why?
|
Neoadjuvant Therapy | 6 | 2024 | 2727 | 0.430 |
Why?
|
Brachytherapy | 1 | 2020 | 1247 | 0.430 |
Why?
|
Prostatic Neoplasms | 6 | 2022 | 11059 | 0.430 |
Why?
|
Antineoplastic Agents | 5 | 2021 | 13691 | 0.410 |
Why?
|
Retrospective Studies | 25 | 2024 | 77410 | 0.370 |
Why?
|
Adenocarcinoma | 2 | 2019 | 6363 | 0.350 |
Why?
|
Neutropenia | 1 | 2014 | 895 | 0.340 |
Why?
|
Carcinoma | 1 | 2020 | 2375 | 0.330 |
Why?
|
Urinary Bladder | 4 | 2023 | 1173 | 0.320 |
Why?
|
Androgen Antagonists | 3 | 2021 | 1376 | 0.320 |
Why?
|
Prostate-Specific Antigen | 4 | 2022 | 2471 | 0.320 |
Why?
|
Survival Rate | 6 | 2021 | 12786 | 0.300 |
Why?
|
Urethra | 2 | 2021 | 407 | 0.300 |
Why?
|
Nasolacrimal Duct | 1 | 2007 | 74 | 0.290 |
Why?
|
Monocytes | 1 | 2016 | 2593 | 0.280 |
Why?
|
Prostatectomy | 3 | 2022 | 1879 | 0.270 |
Why?
|
Aged, 80 and over | 13 | 2023 | 57744 | 0.260 |
Why?
|
Muscles | 4 | 2023 | 1613 | 0.260 |
Why?
|
Neoplasm Staging | 5 | 2024 | 11036 | 0.250 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2022 | 3480 | 0.240 |
Why?
|
Carcinoma, Renal Cell | 1 | 2019 | 3142 | 0.240 |
Why?
|
Cystoscopy | 2 | 2021 | 133 | 0.240 |
Why?
|
Administration, Intravesical | 2 | 2021 | 91 | 0.240 |
Why?
|
Kidney | 1 | 2019 | 7185 | 0.230 |
Why?
|
Aged | 22 | 2023 | 163178 | 0.230 |
Why?
|
Disease-Free Survival | 3 | 2021 | 6895 | 0.230 |
Why?
|
Male | 30 | 2023 | 349776 | 0.230 |
Why?
|
Humans | 45 | 2024 | 743811 | 0.220 |
Why?
|
Pentose Phosphate Pathway | 1 | 2023 | 125 | 0.220 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2011 | 1523 | 0.210 |
Why?
|
Follow-Up Studies | 6 | 2021 | 39001 | 0.200 |
Why?
|
Cohort Studies | 5 | 2021 | 40545 | 0.190 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6539 | 0.190 |
Why?
|
BCG Vaccine | 2 | 2021 | 369 | 0.190 |
Why?
|
Kidney Diseases, Cystic | 1 | 2022 | 186 | 0.180 |
Why?
|
Rewarming | 1 | 2019 | 61 | 0.170 |
Why?
|
Neoplasm Invasiveness | 6 | 2022 | 3617 | 0.170 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2023 | 627 | 0.170 |
Why?
|
Kidney Pelvis | 1 | 2020 | 188 | 0.170 |
Why?
|
Glycolysis | 1 | 2023 | 830 | 0.160 |
Why?
|
Middle Aged | 17 | 2023 | 213241 | 0.160 |
Why?
|
Urethral Obstruction | 1 | 2018 | 56 | 0.160 |
Why?
|
Female | 19 | 2022 | 380020 | 0.160 |
Why?
|
Postoperative Complications | 2 | 2021 | 15281 | 0.160 |
Why?
|
Urologic Surgical Procedures | 1 | 2021 | 301 | 0.160 |
Why?
|
Hypothermia | 1 | 2019 | 189 | 0.150 |
Why?
|
Drug Administration Schedule | 2 | 2019 | 4931 | 0.150 |
Why?
|
Risk Factors | 8 | 2022 | 72252 | 0.150 |
Why?
|
Muscle, Smooth | 1 | 2021 | 934 | 0.140 |
Why?
|
Prognosis | 5 | 2024 | 29052 | 0.140 |
Why?
|
Treatment Outcome | 7 | 2022 | 63042 | 0.140 |
Why?
|
Leukocyte Count | 2 | 2020 | 1588 | 0.140 |
Why?
|
Cell Line, Tumor | 2 | 2023 | 16674 | 0.130 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1676 | 0.120 |
Why?
|
Drug Combinations | 1 | 2019 | 1958 | 0.120 |
Why?
|
Mice, Nude | 1 | 2020 | 3680 | 0.120 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2020 | 2649 | 0.110 |
Why?
|
Immunoenzyme Techniques | 1 | 2017 | 1799 | 0.110 |
Why?
|
Age Factors | 3 | 2019 | 18355 | 0.110 |
Why?
|
Alkaline Phosphatase | 1 | 2016 | 866 | 0.110 |
Why?
|
Reactive Oxygen Species | 1 | 2020 | 2077 | 0.110 |
Why?
|
Radiation Dosage | 1 | 2020 | 1928 | 0.100 |
Why?
|
Lymphocytes | 1 | 2020 | 2615 | 0.100 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2020 | 2504 | 0.100 |
Why?
|
Mice, Inbred BALB C | 1 | 2020 | 6380 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2020 | 2110 | 0.100 |
Why?
|
Mitoxantrone | 1 | 2011 | 152 | 0.090 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2020 | 2938 | 0.090 |
Why?
|
Feasibility Studies | 1 | 2020 | 5078 | 0.090 |
Why?
|
Hemoglobins | 1 | 2016 | 1531 | 0.090 |
Why?
|
Renal Dialysis | 1 | 2019 | 1783 | 0.090 |
Why?
|
Neutrophils | 1 | 2020 | 3718 | 0.070 |
Why?
|
Radiotherapy | 1 | 2014 | 1533 | 0.070 |
Why?
|
Body Weights and Measures | 1 | 2007 | 211 | 0.070 |
Why?
|
Prednisone | 1 | 2011 | 1574 | 0.070 |
Why?
|
Japan | 2 | 2020 | 1360 | 0.070 |
Why?
|
Time Factors | 2 | 2017 | 40038 | 0.060 |
Why?
|
Treatment Failure | 1 | 2011 | 2617 | 0.060 |
Why?
|
Smoking | 1 | 2021 | 8984 | 0.060 |
Why?
|
Cell Proliferation | 1 | 2020 | 10477 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 15067 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7270 | 0.050 |
Why?
|
Adult | 5 | 2021 | 213889 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2021 | 4848 | 0.040 |
Why?
|
Risk Assessment | 1 | 2019 | 23327 | 0.040 |
Why?
|
Stroke Volume | 1 | 2011 | 5002 | 0.040 |
Why?
|
Child, Preschool | 1 | 2020 | 40964 | 0.040 |
Why?
|
Signal Transduction | 1 | 2020 | 23398 | 0.040 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2021 | 2556 | 0.040 |
Why?
|
Carcinoma in Situ | 1 | 2021 | 805 | 0.030 |
Why?
|
Adjuvants, Immunologic | 1 | 2019 | 999 | 0.030 |
Why?
|
Anesthesia, General | 1 | 2021 | 1171 | 0.030 |
Why?
|
Sex Factors | 1 | 2007 | 10394 | 0.030 |
Why?
|
Prostate | 1 | 2022 | 1763 | 0.030 |
Why?
|
Mice | 1 | 2020 | 81154 | 0.030 |
Why?
|
Cell Cycle Proteins | 1 | 2024 | 3463 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2022 | 20121 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2021 | 2265 | 0.020 |
Why?
|
Contrast Media | 1 | 2023 | 5301 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 11524 | 0.020 |
Why?
|
Arrhythmias, Cardiac | 1 | 2019 | 2267 | 0.020 |
Why?
|
Endoscopy | 1 | 2018 | 1781 | 0.020 |
Why?
|
Animals | 1 | 2020 | 168660 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10251 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2021 | 12243 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3503 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12354 | 0.020 |
Why?
|
Child | 2 | 2018 | 77637 | 0.020 |
Why?
|
Electrocardiography | 1 | 2019 | 6441 | 0.020 |
Why?
|
Ultrasonography | 1 | 2018 | 5986 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14714 | 0.020 |
Why?
|
Disease Progression | 1 | 2021 | 13273 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2022 | 35409 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2019 | 15526 | 0.010 |
Why?
|
Adolescent | 1 | 2007 | 85729 | 0.010 |
Why?
|
Prospective Studies | 1 | 2020 | 53250 | 0.010 |
Why?
|